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Abstract 
Aim: The role of advanced glycation end products (AGEs) and their soluble receptor (sRAGE) on the progression and 
prognosis of acute heart failure (HF) was analysed in relation with metabolic parameters as body composition and 
nutritional status.
Methods: A hundred and fifty consecutive patients were included in a prospective clinical study during hospitali‑
zation by acute HF. Detailed medical history, physical examination, electrocardiogram, echocardiogram and vein 
peripheral blood were taken for all patients. During the follow‑up period [297 days (88–422 days)] blood samples for 
biochemical measurements were obtained 1 and 6 months after the inclusion. Dual‑energy X‑ray absorptiometry 
analyses were performed 1 week after discharge.
Results: AGEs and sRAGE levels continuously increased, up to 6 months, after acute HF, but AGEs increase was mainly 
observed in those patients with incident HF. Both AGEs and sRAGE levels were related with bad renal function and 
clinical malnutrition (CONUT score) and they were negatively related with body mass index or percentage of body 
fat. AGEs levels (≥40 a.u.) 1 month after discharge and basal sRAGE levels (>1000 pg/mL) were related with worse 
prognosis in terms of patient death and HF readmission (Log‑rank <0.05 in Kaplan–Meier survival test), independently 
of age, gender, body mass index and other risk factors. Regression models also corroborated this finding.
Conclusions: AGEs and sRAGE are bad prognostic biomarkers for HF and useful markers of HF progression. Since 
their levels seem to be related with clinical malnutrition and body composition these parameters could serve to 
modulate them.
Keywords: Acute heart failure, Advanced glycation end products, Soluble RAGE, Heart failure progression, Heart 
failure prognosis
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Introduction
Heart failure (HF) is a leading cardiovascular problem 
worldwide and increasing evidence demonstrates that 
advanced glycation end products (AGEs) play a pivotal 
role in the development and progression of the disease 
(see for a review [1]). AGEs are generated non-enzy-
matically. Following their interaction with the receptors 
for AGEs (RAGE), a series of events leading to vascular 
and myocardial damage are elicited, resulting in dias-
tolic and systolic dysfunction. Some of the molecular 
mechanisms involved in these events include oxidative 
stress, increased inflammation, enhanced extracellular 
matrix accumulation, and renal damage. Consequently, 
AGEs and soluble RAGE (sRAGE) levels are related to 
the severity [2, 3] and the bad prognosis [3–5] of HF, and 
even to the development of post-infarction HF [6].
The association between sRAGE and incident HF has 
been recently examined in a prospective study (The Ath-
erosclerosis Risk in Communities Study) concluding that 
lower circulating levels of sRAGE are independently 
associated with the development of HF in a community-
based population [7]. However, little is known about the 
evolution of sRAGE and AGEs levels during HF progres-
sion, so prospective studies are needed for this aim. Some 
data suggest AGEs accumulate during cardiovascular 
disease progression, mainly in the context of renal failure 
[8]. It has also been reported that the amount of AGEs 
in cardiomyocytes increases significantly in both diabetes 
and HF [9].
Evolution and progression of HF is also related with 
obesity and body composition. Extensive evidences dem-
onstrate the adverse effects of obesity on central and 
peripheral hemodynamics, as well as on cardiac structure 
and function [10]. This explains the positive relationship 
between body mass index (BMI) and the risk of incident 
HF [11] or cardiovascular disease [12]. However, despite 
the adverse effects of obesity on cardiac structure and 
function, numerous studies have suggested that obese 
patients with HF have a better prognosis than non-obese 
patients, considering obesity as a category of BMI [13], a 
high percentage of body fat [14], or a high waist circum-
ference [15]. This is the so-called “obesity paradox”. These 
data have suggested a possible protective role of body 
fat on HF that can be related with the fact that cardiac 
cachexia is related with cardiac dysfunction. All together 
suggests that even the weight loss recommendation usu-
ally given to obese patients with HF should be taken with 
care and new studies of body composition in patients 
with HF should be made.
AGEs could participate in the complex relationship 
between obesity and the outcome in patients with HF 
[16]. Although the underlying molecular mechanisms are 
far from clear some possibilities have been suggested. On 
one hand, the combined effects in obesity of enhanced 
food consumption, low-energy expenditure, hyperglycae-
mia, hyperlipidaemia and increased oxidative stress may 
boost the formation of AGEs. Moreover, AGEs could be 
formed during the maturation of adipocytes [17]. AGE-
RAGE mediated activation may stimulate inflammatory 
signalling in adipose tissue, resulting in dysregulation of 
adipokines and contributing to the development of obe-
sity-related complications [17]. On the other hand, AGEs 
are possible targets of the protective role of body fat. 
Gaens et  al. [18] suggested that lower levels of circulat-
ing AGE (measured as carboxymethyl lysine) in obesity 
were associated with their trapping into the adipose tis-
sue resulting in lower levels of circulating AGEs. This is 
in accordance with central obesity being characterized by 
chronic low grade inflammation and low levels of circu-
lating AGEs [19]. In subjects on hemodialysis, those who 
naturally accumulate AGEs, the changes in skin autoflu-
orescence (a measurement of AGEs) over 1  year period 
were related to BMI [20]. Accordingly, sRAGE levels, 
which in some conditions could act as a decoy of circu-
lating AGEs, are inversely related with BMI in severely 
obese subjects [21], in young adults [22] and in subjects 
with metabolic syndrome, both adults [23] and adoles-
cents [24].
Taking all these questions into account, our main 
objective was to analyze, for the first time, the role of 
AGEs and sRAGE levels in the progression of HF after 
an episode of acute HF decompensation in relation with 
other metabolic parameters like body composition, body 
fat distribution and nutritional status.
Materials and methods
Subjects
Consecutive patients (≥18  years old) admitted in our 
hospital by the main diagnoses of acute HF were included 
during hospitalization in this prospective observational 
study after signing informed consent. The HF diagnosis 
was made according to the 2016 ESC HF guidelines. If a 
chronic stable HF patient deteriorates it was described as 
“decompensated”, if it was the first admission it was con-
sidered as “de novo” [25]. Main exclusion criteria were 
invasive interventions within the last 6  months, acute 
coronary syndrome in the 3  months preceding admis-
sion, inflammatory disease, autoimmune disease and 
malignant disease. The whole study and protocols were 
approved by the Ethics Committee for Human Studies at 
Galicia (Spanish region) in accordance to the 1975 Decla-
ration of Helsinki.
A complete medical history, serum biochemistry 
with Cobas Integra model 700 multichannel analyser 
(Roche Diagnostics, Indianapolis, USA) and anthropo-
metric data were taken from all patients. Electro- and 
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echo-cardiograms were also performed on each patient 
and peripheral blood samples were obtained for labo-
ratory analysis. The diagnosis of diabetes mellitus was 
based on the latest criteria established by the American 
Diabetes Association [26]. Hypertension was defined as 
systolic/diastolic blood pressure >140/90 mmHg or cur-
rent use of any antihypertensive medication. Dyslipi-
daemia was defined by total cholesterol ≥5.69  mmol/L, 
triglyceride  ≥1.69  mmol/L, high density lipoprotein-
cholesterol (HDL-C)  <1.03  mmol/L, or current use of 
anti-hyperlipidemic drugs. Therapeutic strategy and 
pharmacological treatment were prescribed according to 
Clinical Practice Guidelines published by the European 
Society of Cardiology [27]. The Controlling Nutritional 
Status (CONUT) score was calculated for each patient at 
hospitalization and at discharge. The CONUT includes 
serum albumin, total cholesterol levels, and total lym-
phocyte counts, as indicators of protein reserves, caloric 
depletion and impaired immune defenses, respectively. 
Patients with CONUT scores of 0–1 have a normal nutri-
tional status, those with CONUT scores of 2–4 are at 
mild risk, those with CONUT scores of 5–8 are at mod-
erate risk, and those with CONUT scores of 9–12 are at 
severe risk of malnutrition [28].
Dual energy X‑ray absorptiometry (DEXA)
Body composition (fat mass percentage, fat mass and 
lean mass) was measured 1  week after discharge by 
DEXA (Prodigy, General Electric Medical Systems, Mad-
ison, WI) and the scans were analysed using enCore™ 
software (platform version 13.6, General Electric Medi-
cal Systems, Madison, WI). Patients were classified into 
low or high body fat (BF) and low or high lean mass 
index (LMI) attending to the criteria suggested previ-
ously by Lavie et  al. [29] for both parameters. Low BF 
was considered ≤25% in men and ≤35% in women and 
high BF  >25% in men and  >35% in women. Regarding 
LMI, patients were classified into low LMI for ≤18.9 kg/
m2 in men and  ≤15.4  kg/m2 in women and high LMI 
for >18.9 kg/m2 in men and >15.4 kg/m2 in women.
Measurements and laboratory data
Peripheral blood samples (6  mL) were taken in EDTA-
anticoagulated tubes and plasma were separated by cen-
trifugation (10  min. 1800×g, room temperature) and 
stored at −40 °C until analysis. Samples were taken at the 
time of discharge from the hospital and during the fol-
low-up period at 1 and 6 months after the inclusion.
Estimated glomerular filtration rate (eGFR) was used as 
an indicator of renal function based on the abbreviated 
Modification of Diet in Renal Disease (MDRD) study for-
mula. Cystatin C was measured by a nephelometry kit 
(N Latex Cystatin C; Dade Behring-Siemens Healthcare 
España, Madrid, Spain). AGEs were measured by quan-
titative fluorescence spectroscopy analysis of plasma 
[arbitrary units (a.u.) at 360/40:460/40  nm (excitation: 
emission)] following the protocol previously described 
[30]. By this method, we could measure some differ-
ent AGE modifications at a time (crossline, fluorolink, 
pyrropyridine, vesperlysine, etc.), for which there are 
no immunological-based methods available nowadays. 
The intra-assay and inter-assay coefficients of variation 
were  <4 and  <10%, respectively. Plasma soluble RAGE 
levels were determined using a commercially available 
enzyme-linked immunosorbent assay kit for total solu-
ble RAGE (DRG00, Quantikine; R&D systems, Min-
neapolis, MN, USA) according to the manufacturer’s 
protocol. Measurements were performed in duplicate 
and the results were averaged.
Several biochemical analytes related with diabetes and 
obesity were analysed in plasma at the same time by a 
multiplex kit (Bio-plex™, Bio-Rad, Hercules, CA, USA) 
using magnetic beads attached with the appropriate anti-
bodies by a semi-automatic procedure in a Bio-Plex™ 200 
System (Bio-Rad) following the instructions of the manu-
facturer. Adiponectin plasma levels were measured by 
DuoSet Enzyme-Linked ImmunoSorbent Assay (ELISA) 
kit with a detection limit of 0.6  ng/mL (R&D Systems, 
Minneapolis, MN, USA) following manufacture´s 
protocol.
Follow‑up and endpoints
Events were defined as either cardiac death or admis-
sion due to HF. Cardiac death was noted and confirmed 
by review of the death certificate, hospital chart, and 
physician’s records. The strong study endpoint was the 
combination of cardiac death and readmission by HF. 
The follow-up time was 297  days (inter-quartile range 
188–422 days). During the observation period measure-
ments were not determined for 26 patients at 1 month (6 
of them died) and for 55 patients at 6 months (19 died) 
after discharge.
Data analysis
The statistical analyses were performed with SPSS (Sta-
tistical Package for the Social Sciences), version 17.0. 
The categorical or dichotomous variables were expressed 
as absolute values and percentages, and were com-
pared with the Pearson Ҳ2 test. Normality was checked 
with Kolmogorov–Smirnov test. The continuous vari-
ables were described as the mean ±  standard deviation 
(SD) when normally distributed, or as the median and 
inter-quartile range for non-parametric data. Student 
t test was used for the comparisons of continuous vari-
ables between groups of patients (two tail distribution 
and equal variances between samples). Continuous data 
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from  >2 groups were compared with ANOVA followed 
by Tukey’s test. Non-normal distributed variables were 
compared with Wilcoxon text for two groups or Kruskal–
Wallis test (unrelated data) or Friedman test (related 
data) for  >2 groups comparisons. Correlations between 
variables were calculated by Pearson’s or Spearman’s 
tests according to the normality of the variable. Predic-
tive value of individual variables for new cardiovascular 
events was analysed by receiver operating characteristic 
(ROC) curves. Different Cox proportional hazard analy-
ses were carried out to assess the independency of AGEs 
or sRAGE levels to predict mortality and HF readmission 
and data were presented as hazard ratios (HR) with 95% 
confidence intervals. Kaplan–Meier curves (analyzed 
with log-rank test) were performed to evaluate the prog-
nostic value of AGEs or sRAGE during follow-up. A p 
value of <0.05 was considered statistically significant.
Results
Baseline characteristics and laboratory data
A total of 150 consecutive patients fulfilling the inclu-
sion/exclusion criteria were enrolled in the study from 
mid-2014 to mid-2015. Mean age was 69.9 ± 11.0 years 
and 60.7% were men. Prevalence of arterial hyperten-
sion was 77.3%, hyperlipidemia 57.3% and diabetes mel-
litus 46.0%. Clinical baseline parameters are presented 
in Table 1. Basal levels of AGEs were significantly higher 
in patients with New York Heart Association (NYHA) 
functional class IV than NYHA class II (44.1 ±  14.7 vs. 
33.3 ±  6.4  a.u., p  <  0.05). However, no differences were 
observed between preserved and reduced left ventricular 
ejection fraction (LVEF < 50%).
Ten biochemical parameters related to diabetes and 
obesity were measured by a multiplex kit: c-peptide, 
ghrelin, glucose-dependent insulinotropic polypeptide 
(GIP), glucagon-like peptide-1 (GLP-1), glucagon, insu-
lin, leptin, plasminogen activator inhibitor-1 (PAI-1), 
resistin and visfatin. Adiponectin was also independently 
measured in plasma. Their levels were analyzed in rela-
tion with the appearance of major endpoints (Additional 
file  1: Table S1) and the cut-off points for AGEs and 
sRAGE described below (Additional file 1: Table S2). All 
these parameters with the exception of GIP showed a 
pronounced decrease from discharge to 6  months later, 
showing a marked relation with the acute episode of HF. 
These decreases were independent of the appearance of 
the main endpoint.
These biomarkers were also analyzed in relation with 
the etiology classification of HF showed in Table  1 
(ischemic heart disease, valvular heart disease, hyper-
trophic cardiomyopathy and other causes), but no differ-
ences on these parameters were observed on this regard. 
Particular attention was made on PAI-1 and resistin 
because of their relation with inflammation, but they 
were no different between etiology groups at baseline, 
and at 1 or 6 months after discharge.
Body composition and state of nutrition
Weight and height were measured for all patients at 
the moment of the inclusion and at discharge. 79.2% 
of the patients lost weight during hospitalization 
(3.55  ±  2.97  kg), whereas only 14.1% gained weight 
(1.41 ± 1.78 kg), the rest maintained their same weight. 
Body mass index was 30.3 ± 5.9 for all patients, 29.0 ± 4.8 
for men and 32.4 ± 6.8 for women. Body composition of 
135 patients was analysed 1 week after discharge allowing 
to calculate the percentage of BF and the LMI for each 
patient as well as the total content of visceral fat. 87.4% 
of the patients showed high BF. Patients with high LMI 
were 48.1%. Mean visceral fat was 1878 ± 1114 g, being 
2077 ± 1106 g for men and 1555 ± 1060 for women.
The CONUT score showed that at the time of hospi-
tal admission 20.6% of patients were at normal, 54.0% 
at mild, 21.3% at moderate and 1 patient at severe risk 
of malnutrition. At the time of discharge, 32.0% were 
at normal, 50.0% at mild, 14.7% were at moderate and 
nobody at severe risk of malnutrition. In summary, 23.3% 
of patients reduced their malnutrition risk and only 4.6% 
increased it during hospitalization.
AGEs and sRAGE
AGEs and sRAGE levels were measured at discharge 
 (AGE0 and  sRAGE0) and 1  (AGE1m and  sRAGE1m) and 
6  months  (AGE6m and  sRAGE6m) after discharge. The 
results of these measurements are shown in Fig. 1 and a 
progressive and significant increase in AGEs and sRAGE 
levels is observed up to 6  months after the acute HF. 
However, this progressive increase depends on the pre-
vious history of HF, such that, patients included in the 
study with incident HF (64% of total) showed significant 
increase in levels at  AGE1m and  AGE6m, but not in sRAGE 
levels, although some trend was observed (p = 0.074 and 
p  =  0.064 for  sRAGE1m and  sRAGE6m with respect to 
 sRAGE0, respectively; Additional file 1: Figures S1a, S1b). 
On the contrary, in patients with previous HF sRAGE 
levels progressively increased up to 6  months, whereas 
AGEs levels only increased after 6 months of discharge. 
In a similar way, previous acute myocardial infarction 
(AMI) induced higher increase in  sRAGE1m than no pre-
vious AMI, but it seems not to influence the evolution of 
AGEs levels (Additional file 1: Figures S1c, S1d). Analyz-
ing by the appearance of the main endpoint (death + HF 
readmission) there were no statistical differences in 
the evolution of AGEs or sRAGE levels, although both 
parameters were slightly higher in the group with events 
(Additional file 1: Figures S1e, S1f ).
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Direct association between the CONUT score and the 
levels of  sRAGE0 and  AGE1m were observed. The levels of 
these variables positively increased when risk of malnu-
trition increased (Additional file 1: Figure S2).
AGEs and sRAGE levels showed an inverse relation-
ship with several parameters of obesity. Basal AGEs 
negatively related with BMI (rs  =  −0.175; p  =  0.037) 
and  sRAGE1m levels were negatively related with BF per-
centage (rs = −0.259; p = 0.014).  AGEs1m and  sRAGE1m 
were lower in the highest quartile of BF percentage than 
in the lowest (38.2 [33.2–50.0] vs. 43.4 [39.2–53.8] a.u., 
p = 0.038 for  AGEs1m; 1017.0 [780.5–1577.0] vs. 1661.0 
[898.0–2843.0] pg/mL, p = 0.041 for  sRAGE1m). Soluble 
 RAGE1m were also lower in obese (BMI > 30 kg/m2) than 
Table 1 Baseline clinical characteristics of  the patients. Data presented for  the total population and  for the groups 
with or without cardiovascular events during the follow-up
ACE angiotensin‑converting enzyme, AMI acute myocardial infarction, ARB angiotensin receptor blocker, BF body fat, BMI body mass index, CONUT controlling 
nutritional status score, DM diabetes mellitus, eGFR MDRD estimated glomerular filtration rate by modification of diet in Renal Disease formula, Hb haemoglobin, 
HbA1c glycated haemoglobin, HDLc high density lipoprotein cholesterol, HF heart failure, HLP hyperlipidaemia, HTA arterial hypertension, LDLc low density lipoprotein 
cholesterol, LMI lean mass index, NT-proBNP N‑terminal pro b‑type natriuretic peptide
Total population (n = 150) Cardiovascular event (−) (n = 111) Cardiovascular event (+) (n = 39) p value
Age (years) 69.9 ± 11.0 68.7 ± 11.4 73.4 ± 9.1 0.024
Male, % 60.7 57.7 69.2 0.139
HTA, % 77.3 75.7 82.1 0.280
HLP, % 57.3 51.4 74.4 0.010
DM, % 46.0 43.2 53.8 0.169
Smoker, % 12.7 14.4 7.7 0.323
Previous AMI, % 18.0 11.7 35.9 0.001
Aetiology of HF, %
 Ischemic heart disease 28.0 24.6 46.2 0.001
 Valvular heart disease 15.3 13.5 20.5
 Hypertrophic cardiomyopathy 4.0 2.7 7.7
 Other causes 52.7 62.2 25.6
Systolic pressure, mmHg 114.9 ± 17.2 113.8 ± 17.0 118.1 ± 17.6 0.184
Diastolic pressure, mmHg 66.4 ± 12.1 67.0 ± 11.3 64.7 ± 14.1 0.322
Laboratory data
 Glucose, mg/dL 131.5 [103.0–177.7] 126.5 [102.5–176.2] 140.0 [104.5–192.7] 0.561
 NT‑proBNP, pg/mL 2894 [1109–6822] 2386 [1048–4751] 6173 [1774–12723] <0.001
 Hb, g/dL 13.2 ± 1.9 13.3 ± 1.8 12.9 ± 2.2 0.249
 HbA1c, % 6.1 [5.7–6.8] 6.1 [5.7–6.7] 6.1 [5.7–7.2] 0.430
 Triglyceride, mg/dL 94 [69–121] 93 [70–124] 99 [64–120] 0.641
 HDLc, mg/dL 39 [32–49] 39 [34–49] 39 [28–50] 0.432
 LDLc, mg/dL 83 [63–106] 91 [68–112] 63 [50–79] <0.001
 eGFR MDRD, mL/min/1.73 m2 74.3 ± 30.0 80.1 ± 30.9 57.4 ± 19.2 <0.001
Echo‑ and electro‑cardiogram data
 LVEF, % 42.9 ± 15.6 42.9 ± 14.6 42.7 ± 18.4 0.957
 LV end‑diastolic volume, mL 156.6 ± 71.0 150.4 ± 69.2 180.1 ± 74.5 0.096
Body composition and nutrition
 BMI, kg/m2 29.3 [26.1–33.3] 28.9 [25.9–34.2] 29.6 [27.1–32.5] 0.560
 BF, % 37.7 ± 9.6 37.9 ± 10.0 36.9 ± 8.5 0.577
 LMI, kg/m2 17.5 ± 3.0 17.3 ± 2.9 18.1 ± 3.1 0.204
 Visceral fat, g 1878 ± 1114 1836 ± 1102 2001 ± 1158 0.459
 CONUT score 2 [1–4] 2 [1–4] 3 [2–5] 0.056
Medication, %
 ACE inhibitors and/or ARBs, % 89.3 91.9 82.1 0.083
 β blockers, % 78.7 79.3 76.9 0.459
 Ca channel blockers, % 13.3 13.5 12.8 0.578
 Statins, % 64.7 58.6 82.1 0.029
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“normal” BMI patients (BMI < 25 kg/m2; 1043.0 [702.7–
1588.5] vs. 1603.5 [1183.7–2613.2] pg/mL, p  =  0.022). 
Bad renal function measured by creatinine levels was 
related with both  AGE1m (rs  =  0.315; p  =  0.001) and 
 sRAGE1m levels (rs = 0.267; p = 0.008). Even more, AGE 
levels (at all times) and  sRAGE1m levels were signifi-
cantly higher in the group of patients with eGFR <60 mL/
min/1.73  m2 (39.7 [34.5–47.9] vs. 51.0 [40.0–63.7] 
a.u., p =  0.001 for  AGE1m and 982.0 [673.0–1444.0] vs. 
1081.0 [697.0–1737.0] pg/mL, p =  0.004 for  sRAGE1m). 
This relationship with renal function is well known and 
established.
Follow‑up data
The value of AGE and sRAGE levels to predict new events 
(defined by the combination of death and HF readmission) 
after acute HF were analysed by receiver operating char-
acteristic (ROC) curves. A total of 39 patients suffered an 
event during the follow-up period and the clinical param-
eters for this group in comparison with event-free patients 
are presented in Table  1.  AGE1m was the one that pre-
sented a better area under the curve of the three values of 
AGE levels [0.613 95% CI (0.499, 0.727)]. From that curve 
we obtained a cut-off value of 40 a.u.  AGE1m (0.8 sensitiv-
ity, 0.5 specificity) for predicting death and HF readmis-
sion. Interestingly,  AGE1m levels were positively related 
with NT-proBNP levels (a known biomarker of HF). 
 sRAGE0 showed an area under the ROC curve of 0.621 
[95% CI (0.516, 0.725)] and from that curve we selected 
a cut-off value of 1000 pg/mL (0.6 sensitivity, 0.5 specific-
ity). These cut-off values for  AGE1m and  sRAGE0 served to 
predict worse prognosis of patients in terms of death and 
HF readmission (Long-rank < 0.05 in Kaplan–Meier sur-
vival tests; Fig. 2). Multivariate analyses by Cox regression 
models also corroborated this finding. The best regression 
model was for the variables presented in Table 2. Presence 
of hyperlipidaemia (HLP), NT-proBNP levels (measured 
in 100 pg/mL steps) and more than 40 a.u. of  AGE1m were 
predictors of cardiovascular events (considering death or 
HF readmission) after acute HF, adjusted by age, gender, 
diabetes mellitus, eGFR <60 mL/min/1.73  m2, sRAGE lev-
els and LMI.
Basal biochemical parameters showed no differences 
between event- and event-free groups, unless for GLP-1 
and glucagon, both being significantly higher in the 
event-group (Additional file  1: Table S1). Regarding the 
cut-off predicting values of  AGE1m and  sRAGE0 only 
basal levels of c-peptide and resistin were higher when 
 AGE1m > 40 a.u. whereas PAI-1 was lower. In the case of 
 sRAGE0 >1000 pg/mL only basal insulin was significantly 
lower (Additional file 1: Table S2).
Discussion
In this work, the evolution of AGEs and sRAGE lev-
els during the 6  months following an acute HF episode 
of decompensation is studied for the first time. AGEs 
and sRAGE levels continuously increased in this period, 
but the increase of AGEs was mainly observed in those 
Fig. 1 AGEs (a) and sRAGE (b) plasma levels at time of discharge and after 1 or 6 months. Boxes represent interquartile ranges with median as 
horizontal line. Vertical bars demarcate the maximum to minimum range. *p <0.05 vs. basal values, # <0.05 vs. 1 month levels, by Wilcoxon test
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patients with incident HF. This relation with the evolu-
tion of HF is a novel finding of this work. It was also con-
firmed that sRAGE levels are predictive biomarkers of 
bad HF prognosis independent of age, gender, body mass 
index and other risk factors, in a 1-year follow-up period. 
Interestingly, high  AGE1m levels after the acute decom-
pensation are also indicative of a worse clinical outcome 
in terms of cardiovascular death and HF readmission. 
Finally, AGEs and sRAGE levels showed a direct associa-
tion with clinical malnutrition (CONUT score), but an 
inverse relation with BMI or the percentage of body fat.
Basal levels of AGEs were related to the severity of the 
HF in terms of NYHA functional classes at the time of 
hospital admission, but not in relation with preserved 
or reduced ejection fraction. On the contrary, sRAGE 
did not show this relationship with HF severity. These 
results are different than those previously observed in 
patients with chronic HF, where sRAGE levels correlated 
with NYHA class [2, 5]. However, it should be taken 
into account that in the present study we are analyzing 
patients in the moment of the acute decompensation 
by HF, most of them in class III and IV, and that 64% 
of these patients are cases of incident HF. In the previ-
ously mentioned studies the patients presented chronic 
and stable HF with a more homogeneous distribution 
over the NYHA classes. In this sense, the influence of 
the inflammatory status of each patient in the moment of 
sampling could affect AGEs or sRAGE levels. However, 
the levels measured in this work for PAI-1 and resistin, 
two cytokines that have been related with the sub-clinical 
inflammatory status [31, 32], were no different regarding 
the cutoff point of  sRAGE0, and they were contradictory 
regarding the cutoff point of  AGE1m: whereas resistin was 
higher in the group of  AGE1m > 40 a.u., PAI-1 was lower.
Moreover, we did not observe differences in sRAGE 
levels between patients with preserved or reduced LVEF 
as Willensen et  al. [33] did, but we considered reduced 
LVEF as <50% whereas they used <40%. A possible expla-
nation for these differences could arise from one of the 
novel findings of this work: AGEs and sRAGE levels 
increase during the development of HF. At least during 
6 months following an acute decompensation by HF, both 
biomarkers continuously increased their values, being 
this event more evident for AGEs in the case of incident 
HF. Therefore, the levels of these biomarkers seem to be 
influenced by the stage of the HF. Our data show that 
AGEs levels increase noticeably after an acute episode of 
incident HF, whereas sRAGE seems to react in the same 
way, but with a slower rate, which is why the increase is 
better observed in patients with previous HF. This means 
that AGEs and sRAGE levels are not only biomarkers of 
Fig. 2 Cumulative survival curves during the follow‑up period for patients grouped accordingly to the AGE levels at 1 month of discharge  (AGE1m) 
by the cut‑off point of 40 a.u. (a) or by the cut‑off point of 1000 pg/mL of basal sRAGE  (sRAGE0) concentration (b). Survival was considered free of 
death or HF readmission. Kaplan–Meier curves were analysed with log‑rank test and their p value is showed
Table 2 Multivariate analysis for AGE to predict follow-up 
mortality and HF readmission after discharge for acute HF
eGFR60 estimated glomerular filtration rate <60 mL/min/1.73 m
2, HLP 
hyperlipidaemia, LMI Lean mass index, NT-proBNP100 N‑terminal pro b‑type 
natriuretic peptide in 100 pg/mL steps
Values in italics denote statistically significant differences
Multivariate model (adjusted by age, gender,  eGFR60, diabetes mel‑
litus and LMI)
Variable HR CI 95% p
HLP 2.870 1.145–7.195 0.025
NT‑proBNP100 1.006 1.002–1.010 0.007
AGE1m > 40 a.u. 2.775 1.080–7.130 0.034
sRAGE0 > 1000 pg/mL 2.064 0.901–4.728 0.086
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the severity of HF, but also of its progression. This is an 
important point since the rest of the biomarkers meas-
ured in the study, all related with diabetes and obesity, 
showed the opposite relationship with acute HF. They all 
presented a marked reduction from their elevated levels 
during hospitalization, to lower levels during the months 
following the discharge.
AGE-RAGE axis seems to be related to the nutri-
tional status of patients since CONUT scores indicating 
risk of malnutrition were directly associated with AGE 
and sRAGE levels. This is an interesting and new find-
ing, which is in accordance with the inverse relationship 
observed between AGE and sRAGE levels with respect to 
parameters of obesity such as BMI or BF percentage. We 
previously commented that sRAGE levels were inversely 
related to BMI in severely obese subjects [21], in young 
adults [22] and in subjects with metabolic syndrome either 
adults [23] or adolescents [24]. More recently, the inverse 
relationship between sRAGE and BMI was observed 
in healthy women [34]. Soluble RAGE levels were also 
inversely associated with fat mass, and in patients with 
prediabetes [35], where it also was negatively correlated 
with body weight and waist and hip circumferences. As we 
will discuss below, high sRAGE levels are indicators of bad 
prognosis in the population under study. Therefore, these 
findings support the hypothesis of the so-called “obese 
paradox”, by which obesity and particularly body fat, have 
shown to be protective in the context of HF [14]. In this 
case, high BMI and BF correlate with lower sRAGE levels, 
predicting a better outcome than in patients with higher 
sRAGE levels and lower BMI and BF.
The relationship between AGEs and obesity seems to 
be more complex. According to previous data [17], AGEs 
accumulation in adipose tissue could explain our findings 
about the inverse relationship between AGEs levels and 
BMI, which agrees with previous results [18, 19], but dis-
agrees with Amin et al. [36], that found a positive relation 
between AGEs, measured as carboxymethyl lysine, and 
BMI. Although the mechanisms are controversial, AGEs 
can be absorbed from diet. In this sense, whereas low-
AGE diets can increase insulin sensitivity [37], high-AGE 
diets are related with increased fat intake and higher risk 
of abdominal obesity [38]. However, metabolic syndrome 
can make the difference: serum AGEs levels and AGEs 
consumption from diet are higher in obese people with 
metabolic syndrome than in obese without metabolic 
syndrome [39]. Once in the body, RAGE mediates AGE 
accumulation in adipose tissue [18], and RAGE activation 
can induce the production of inflammatory mediators in 
adipocytes that could ultimately lead to dysregulation of 
adipokines in obesity [17].
Present data confirm previous findings about the pre-
dictive value of AGE-RAGE axis for worse prognosis in 
HF for AGEs [3, 6] and sRAGE [4, 5] levels. Calculated 
cut-off values for  AGE1m and  sRAGE0 served to predict 
death and HF readmission in the univariate analyses. 
The best regression model included hyperlipidemia, NT-
proBNP levels and more than 40 a.u. of  AGE1m as predic-
tors of death or HF readmission after acute HF, adjusted 
by age, gender, renal function, diabetes mellitus and LMI. 
These results partially agree with those recently reported 
by Willensen et  al. [33] where AGE predicted hospitali-
zation for HF and the combination of mortality and HF 
hospitalization whereas sRAGE did not predict events 
with statistical signification. Apart from the direct molec-
ular damage of the activity of AGE-RAGE axis in cells, 
tissues and organs of the cardiovascular system [1], high 
AGE levels in plasma severely affect kidney function. This 
damage is always reflected by the positive correlation 
between AGE and sRAGE levels and parameters indicat-
ing bad renal function. Renal impairment is common in 
HF, and strongly associated with poor outcome [40], so 
this could be one reason for the bad prognostic value of 
AGE and sRAGE in this study.
Another possible reason is the relation with energetic 
metabolism and obesity in our population. We have pre-
viously commented the relationship between AGE and 
sRAGE levels with malnutrition. Moreover, high AGEs 
levels were related to higher concentrations of c-peptide 
and resistin in plasma and to lower concentration of PAI-
1, suggesting some relation with the modulation of insu-
lin secretion and insulin resistance for AGEs. PAI-1 can 
respond to increased inflammation and fibrosis, but also 
to obesity or metabolic syndrome [41]. Intriguingly, low 
levels of insulin were observed in patients with higher lev-
els of sRAGE. The group of patients with events showed 
higher levels of glucagon and GLP-1, suggesting an 
enhanced gluconeogenesis and aside from this, a possible 
implication of increased energy expenditure and decrease 
of adipose tissue expansion in this group of patients [42].
Finally, although do not directly supported by our data, 
we cannot forgot that AGEs have been demonstrated to 
participate in the structural modification and functional 
alteration of the extracellular matrix proteins in vessels 
and myocardium, as well as in the intracellular signals 
mediated by calcium in cardiovascular cells [1, 43]. All 
these mechanisms would also contribute to explain the 
pathophysiological role of AGE/RAGE axis on HF.
Conclusions
As the conclusion of the work, both AGEs and sRAGE 
seem to be fine biomarkers of bad prognosis for HF. 
However, the main novelty is related with the evolution 
of AGE/RAGE axis in relation with HF. AGEs and sRAGE 
levels increase at the beginning of the pathology, being 
useful for following HF progression. Since this increase 
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seems to be related with clinical malnutrition and nega-
tively correlated with body fat quantity, these parameters 
could serve to modulate their levels in a trend to improve 
HF clinical outcome.
Limitations
The main limitation of our study is the number of 
patients included. This reduces the potency of the sta-
tistical analysis. Further research in large populations is 
needed to confirm our findings. Secondly, our study was 
made only in patients after an acute episode of HF, so, 
the results can be different in patients with chronic and 
established HF. Thirdly, the culprit mechanism of the 
acute episode of HF is unknown in most of the patients, 
so differences between patients with regard to this could 
not be explored. Fourthly, sampling during the follow-up 
occurred at only three time points, hence it is not pos-
sible to know what happens in the periods in between. 
Fifthly, AGE measurement was done for a group of modi-
fications, as explained, not for all the types of AGEs or 
for only a specific AGE, so, 1) the results cannot be 
extrapolated to all the AGEs and 2) the specific effect of 
one single AGE of the type of AGEs measured cannot be 
extracted from the whole.
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